Revelation Biosciences GAAP EPS of -$5.92 (NASDAQ:REVB)
Revelation Biosciences reported a Q3 GAAP EPS of -$5.92. The company had $9.1M in cash as of September 30, 2026, down from $10.7M at the end of 2025, according to the company.
How this was made
The 30-second read
Why it matters
The earnings miss and cash reduction are likely to trigger short‑term selling pressure, especially in a thinly traded micro‑cap environment.
Market read
First‑time earnings disclosure for a micro‑cap biotech; negative results suggest near‑term downside risk.
What to watch
Potential upcoming clinical trial milestones or partnership announcements not covered in this brief could offset the negative earnings.
Background
Revelation Biosciences (NASDAQ:REVB) released its Q3 2026 earnings, showing a GAAP loss of $5.92 per share and a cash balance decline from $10.7M to $9.1M.
Ticker impact
Q3 2026 GAAP EPS reported at -$5.92 and cash down to $9.1M, first disclosure of the quarter's results.
downward pressure as investors price in the loss per share and reduced cash balance
The press release provides the first earnings numbers, showing a sizable loss and a cash decline, which typically triggers sell pressure for a micro‑cap biotech.
Market effects
May weigh on other small‑cap biotech stocks as investors reassess cash runway expectations.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact given the company's size and niche focus.
Counterpoint
If the loss reflects a strategic R&D investment, the stock could be undervalued relative to future pipeline potential.
Key entities
- companyRevelation Biosciences
Biotech firm listed on NASDAQ under ticker REVB.